Lucentis Shows Significant Vsion Benefits In Pivotal Phase III Data

Vision Loss Drug

Lucentis the first drug shown to improve vision in patients with "wet" age-related macular degeneration (AMD), the leading cause of blindness in people over age 60

Vision benefits of Lucentis sustained in two years of treatment

Lucentis blocks all biologically active forms of vascular endothelial cell growth factor A (VEGF-A), a molecule believed to be the major underlying cause of wet AMD

Two pivotal Phase III clinical trials (MARINA and ANCHOR) published in The New England Journal of Medicine demonstrate that Lucentis (ranibizumab) treatment maintains or improves vision in patients with wet age-related macular degeneration (AMD), the leading cause of blindness in people over age 60.

The two Phase III, multi-center, randomized, double-masked studies in 1,139 wet AMD patients compared Lucentis treatment to sham control (the MARINA trial) or active control (the ANCHOR trial). Results after two years of treatment (MARINA) and one year (ANCHOR) were published in the US medical journal.

Lucentis has been approved for treatment of wet